Redeye leaves a comment on the Q4 report published by Alzinova earlier today. Overall, the report did not include any major surprises. Following the positive results from the phase Ib study with ALZ-101, the main focus ahead will be to achieve a licensing deal. For now, we reiterate our fair value range (SEK2 – SEK24) with a base case valuation of SEK12.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Alzinova Q4 – With wind in the sails

© Modular Finance, source Nordic Press Releases